Do I need a prescription for Phytomenadione 10mg tablets?

Phytomenadione 10mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Phytomenadione 10mg tablets?

Phytomenadione 10mg tablets is the generic name. It is available under brand names including: AmPhytom 10mg tablets, Konakion 10mg tablets, Phyto-K 10mg tablets, Phytomenadione 10mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Phytomenadione 10mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

10mg

Oral

Vitamins

Active ingredients:

Phytomenadione

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 09.06.06

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC B02BA01

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Phytomenadione

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Phytomenadione

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Browse all Drug Analysis Profiles A–Z

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Phytomenadione

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

4 branded products available

4 productsShow details

Part of the Konakion brand family (generic: Phytomenadione)

4 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Phytomenadione on the MHRA register

AmPhytom 10mg tablets

Essential-Healthcare Ltd

None

Phyto-K 10mg tablets

TriOn Pharma Ltd

None

Phytomenadione 10mg tablets

Special Order

None

Special

Konakion 10mg tablets

Roche Products Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

20 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Phytomenadione 30micrograms/ml oral solution

Oral solution

Same therapeutic group

Menadiol 10mg capsules

Capsule

10mg

Same therapeutic group

Phytomenadione 100microgram tablets

Tablet

Same therapeutic group

Phytomenadione 500micrograms/5ml oral suspension

Oral suspension

5ml

Same therapeutic group

Phytomenadione 500micrograms/5ml oral solution

Oral solution

5ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Phytomenadione

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Phytomenadione

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

41987411000001100

dm+d ID

41987411000001100

VTM (Virtual Therapeutic Moiety)

777194004

VMP (Virtual Medicinal Product)

41987411000001100

BNF code

09060600

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

B02BA01

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

22 minutes

Mechanism

Vitamin K is a cofactor of gamma-carboxylase.

Food interactions

None known

Human targets

3 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

4 µg

A 4 µg oral dose of phylloquinone is 13% ± 9% bioavailable, with a T_max of 4.7…

Half-life

22 minutes

Intravenous phylloquinone has an initial half life of 22 minutes, followed by a half life of 125 minutes.
[A234104]

Volume of distribution

6 L

The steady state volume of distribution of phylloquinone is 20 ± 6 L in subjects who are also taking phenprocoumon therapy.
[A234374]

Metabolism

Phylloquinone's phytyl side chain is omega hydroxylated by CYP4F2.
[A137578]…

Elimination

36%

Intravenous phylloquinone is 36% eliminated in the feces in 5 days and 22% recovered in urine in 3 days.
[A234104][A234329]

Clearance

90%

Intravenous phylloquinone is 90% cleared in 2 hours, and 99% cleared in 8 hours.
[A234104][A234329]…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Vitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin.[L33319][L33345] Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates precursors to coagulation factors II, VII, IX, and X.[A234264][A234195][A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity of vitamin K.[L33319]

Phylloquinone has been synthesized since at least 1939,[A234384] and was approved by the FDA prior to 1955.[L33389]

Properties:

liquid

Avg. mass: 450.70 Da

DrugBank indication

Oral phylloquinone is indicated to treat prothrombin deficiency caused by coumarin or indanedione derivatives; and hypoprothrombinemia secondary to antibacterial therapy, salicylates, or obstructive jaundice or biliary fistulas with concomitant bile salt administration.
[L33345]

Parenteral (intravenous, intramuscular, and subcutaneous) phylloquinone is indicated to treat coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by vitamin K deficiency or some interference with vitamin K activity.
[L33319]
These indications include the above indications as well as hypoprothrombinemia secondary to sprue, ulcerative colitis, celiac disease, intestinal resection, pancreatic cystic fibrosis, or regional enteritis; or hypoprothrombinemia caused by interference with vitamin k metabolism.
[L33319]

Also known as(47)

2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione

2-Methyl-3-[(2E)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone

2-Methyl-3-phytyl-1,4-naphthochinon

2-Methyl-3-phytyl-1,4-naphthoquinone

3-Phytylmenadione

alpha-Phylloquinone

Fitomenadiona

Phyllochinon

Dosage forms(90)

Solution / drops (Oral)

Tablet (Oral)

Solution (Parenteral) — 10.000 mg

Injection, emulsion (Intramuscular; Intravenous; Subcutaneous) — 10 mg/1mL

Injection, emulsion (Intramuscular; Intravenous; Subcutaneous) — 2 mg/1mL

Tablet, effervescent (Oral)

Tablet, effervescent (Oral) — 2500 mg

Capsule, liquid filled; kit; tablet (Oral)

Molecular properties(18)

Drug interactions(739)

Known interactions with other medications. Always consult a healthcare professional.

Orlistat

Moderate

DB01083

Orlistat can cause a decrease in the absorption of Phylloquinone resulting in a reduced serum concentration and potentially a decrease in efficacy.

Check this interaction

Dicoumarol

Moderate

DB00266

The therapeutic efficacy of Dicoumarol can be decreased when used in combination with Phylloquinone.

Check this interaction

Phenindione

Moderate

DB00498

The therapeutic efficacy of Phenindione can be decreased when used in combination with Phylloquinone.

Check this interaction

Warfarin

Moderate

DB00682

The therapeutic efficacy of Warfarin can be decreased when used in combination with Phylloquinone.

Check this interaction

Phenprocoumon

Moderate

DB00946

The therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Phylloquinone.

Check this interaction

Acenocoumarol

Moderate

DB01418

The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Phylloquinone.

Check this interaction

4-hydroxycoumarin

Moderate

DB03410

The therapeutic efficacy of 4-hydroxycoumarin can be decreased when used in combination with Phylloquinone.

Check this interaction

Coumarin

Moderate

DB04665

The therapeutic efficacy of Coumarin can be decreased when used in combination with Phylloquinone.

Check this interaction

(R)-warfarin

Moderate

DB08496

The therapeutic efficacy of (R)-warfarin can be decreased when used in combination with Phylloquinone.

Check this interaction

Ethyl biscoumacetate

Moderate

DB08794

The therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Phylloquinone.

Check this interaction

Fluindione

Moderate

DB13136

The therapeutic efficacy of Fluindione can be decreased when used in combination with Phylloquinone.

Check this interaction

Clorindione

Moderate

DB13275

The therapeutic efficacy of Clorindione can be decreased when used in combination with Phylloquinone.

Check this interaction

Diphenadione

Moderate

DB13347

The therapeutic efficacy of Diphenadione can be decreased when used in combination with Phylloquinone.

Check this interaction

Tioclomarol

Moderate

DB13451

The therapeutic efficacy of Tioclomarol can be decreased when used in combination with Phylloquinone.

Check this interaction

(S)-Warfarin

Moderate

DB14055

The therapeutic efficacy of (S)-Warfarin can be decreased when used in combination with Phylloquinone.

Check this interaction

Mineral oil

Unknown severity

DB11057

The serum concentration of Phylloquinone can be decreased when it is combined with Mineral oil.

Check this interaction

Cyclosporine

Moderate

DB00091

Cyclosporine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Icosapent

Moderate

DB00159

Icosapent may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Cefotiam

Moderate

DB00229

Cefotiam may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Mesalazine

Moderate

DB00244

Mesalazine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Cefmenoxime

Moderate

DB00267

Cefmenoxime may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Cefmetazole

Moderate

DB00274

Cefmetazole may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Pamidronic acid

Moderate

DB00282

Pamidronic acid may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Tenofovir disoproxil

Moderate

DB00300

Tenofovir disoproxil may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Indomethacin

Moderate

DB00328

Indomethacin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Cidofovir

Moderate

DB00369

Cidofovir may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Cefpiramide

Moderate

DB00430

Cefpiramide may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Ceftazidime

Moderate

DB00438

Ceftazidime may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Loracarbef

Moderate

DB00447

Loracarbef may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Cefalotin

Moderate

DB00456

Cefalotin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Nabumetone

Moderate

DB00461

Nabumetone may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Ketorolac

Moderate

DB00465

Ketorolac may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Tenoxicam

Moderate

DB00469

Tenoxicam may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Celecoxib

Moderate

DB00482

Celecoxib may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Cefotaxime

Moderate

DB00493

Cefotaxime may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Tolmetin

Moderate

DB00500

Tolmetin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Foscarnet

Moderate

DB00529

Foscarnet may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Rofecoxib

Moderate

DB00533

Rofecoxib may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Piroxicam

Moderate

DB00554

Piroxicam may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Methotrexate

Moderate

DB00563

Methotrexate may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Cephalexin

Moderate

DB00567

Cephalexin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Fenoprofen

Moderate

DB00573

Fenoprofen may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Valaciclovir

Moderate

DB00577

Valaciclovir may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Valdecoxib

Moderate

DB00580

Valdecoxib may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Diclofenac

Moderate

DB00586

Diclofenac may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Sulindac

Moderate

DB00605

Sulindac may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Bacitracin

Moderate

DB00626

Bacitracin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Amphotericin B

Moderate

DB00681

Amphotericin B may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Cephaloglycin

Moderate

DB00689

Cephaloglycin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Flurbiprofen

Moderate

DB00712

Flurbiprofen may decrease the excretion rate of Phylloquinone which could result in a higher serum level.

Check this interaction

Showing 50 of 739 interactions

Toxicity & overdose

High doses of vitamin K1 are not associated with toxicity.
[A234259]
Intravenous administration has been associated with an increased risk of toxicity.
[A234284]
These patients should be treated with symptomatic and supportive measures.

The intravenous LD₅₀ in mice is 1170 mg/kg and the oral LD₅₀ is >24180 mg/kg.
[L33345]

How it works

Mechanism of action

Vitamin K is a cofactor of gamma-carboxylase.[A234264][A234195] Gamma carboxylase attaches carboxylic acid functional groups to glutamate, allowing precursors of factors II, VII, IX, and X to bind calcium ions.[A234259] Binding of calcium ions converts these clotting factors to their active form, which are then secreted from hepatocytes into the blood, restoring normal clotting function.[L33345]

Vitamin K may also carboxylate matrix proteins in chondrocytes, inhibiting calcification of joints, and may increase type II collagen.[A234304] The role of vitamin K in osteroarthritis,[A234304] bone density,[A234309] and vascular calcification[A234314] is currently under investigation.

Pharmacodynamics

Phylloquinone is a vitamin K indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity of vitamin K.[L33319] It has a long duration of action as vitamin K is cycled in the body,[A234259] and a wide therapeutic index as large doses can be tolerated.[A234284][L33345] Patients should have their prothrombin time monitored during therapy and healthcare professionals should be aware of the increased risk of hypersensitivity reactions with parenteral administration.[L33345]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

A 4 µg oral dose of phylloquinone is 13% ± 9% bioavailable, with a T_max of 4.7 ± 0.8 hours.
[A234264]
1.5 ± 0.8 nmol is found in the plasma compartment, and 3.6 ± 3.4 nmol is found in the second compartment.
[A234264]

A 10 mg intramuscular phylloquinone dose is 89.2% ± 25.4% bioavailable.
[A234344]
The same dose reaches a mean C_max of 67 ± 30 ng/mL, with a mean T_max of 9.2 ± 6.6 hours, and an AUC of 1700 ± 500 h\*ng/mL.
[A234344]

A 10 mg intravenous phylloquinone dose has a mean AUC of 1950 ± 450 h\*ng/mL.
[A234344]

Half-life

Intravenous phylloquinone has an initial half life of 22 minutes, followed by a half life of 125 minutes.
[A234104]

Volume of distribution

The steady state volume of distribution of phylloquinone is 20 ± 6 L in subjects who are also taking phenprocoumon therapy.
[A234374]

Metabolism

Phylloquinone's phytyl side chain is omega hydroxylated by CYP4F2.
[A137578]
The side chain is then cleaved to 5 or 7 carbons long, and then glucuronidated prior to elimination.
[A234104][A234109][A234114][A234119]

Vitamin Ks in general undergo a cycle of reduction to vitamin K hydroquinone by vitamin K epoxide reductase (VKOR), oxidation to vitamin K epoxide by gamma-glutamyl carboxylase, and converted back to vitamin K by VKOR.
[A234259]

Route of elimination

Intravenous phylloquinone is 36% eliminated in the feces in 5 days and 22% recovered in urine in 3 days.
[A234104][A234329]

Clearance

Intravenous phylloquinone is 90% cleared in 2 hours, and 99% cleared in 8 hours.
[A234104][A234329]
A 10 mg intravenous dose of phylloquinone has a mean clearance of 91 ± 24 mL/min.
[A234344]

Drug targets(3)

Proteins and enzymes this drug interacts with in the body

Vitamin K-dependent gamma-carboxylase

BE0000403

GGCX

substrate

inducer

cofactor

Specific functiongamma-glutamyl carboxylase activity

Cellular location

Endoplasmic reticulum membrane

General function & pharmacology

Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vitamin K to vitamin K epoxide .
PMID:17073445
Catalyzes gamma-carboxylation of various proteins, such as blood coagulation factors (F2, F7, F9 and F10), osteocalcin (BGLAP) or matrix Gla protein (MGP) PMID:17073445

Prothrombin

BE0000048

cofactor

Specific functioncalcium ion binding

Cellular location

Secreted, extracellular space

General function & pharmacology

Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing. Activates coagulation factor XI (F11); activation is promoted by the contact with negatively charged surfaces .
PMID:2019570 PMID:21976677
Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL8/CXCL8, in endothelial cells PMID:30568593 PMID:9780208

Osteocalcin

BE0000724

BGLAP

agonist

Specific functioncalcium ion binding

Cellular location

Secreted

General function & pharmacology

Bone protein that constitutes 1-2% of the total bone protein, and which acts as a negative regulator of bone formation .
PMID:3019668 PMID:6967872
Functions to limit bone formation without impairing bone resorption or mineralization (By similarity). It binds strongly to apatite and calcium PMID:6967872

Metabolizing enzymes(3)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP4F2Cytochrome P450 4F2

substrate

UBIAD1UbiA prenyltransferase domain-containing protein 1

substrate

VKORC1Vitamin K epoxide reductase complex subunit 1

substrate

product of

Biological pathways(25)

Warfarin Action Pathway

Involved compounds

Calcium,Phylloquinone,Warfarin

Acenocoumarol Action Pathway

Involved compounds

Acenocoumarol,Calcium,Phylloquinone

Dicumarol Action Pathway

Involved compounds

Calcium,Dicoumarol,Phylloquinone

Phenprocoumon Action Pathway

Involved compounds

Calcium,Phenprocoumon,Phylloquinone

Enoxaparin Action Pathway

Involved compounds

Ardeparin,Calcium,Phylloquinone

Fondaparinux Action Pathway

Involved compounds

Calcium,Fondaparinux,Phylloquinone

Heparin Action Pathway

Involved compounds

Calcium,Heparin,Phylloquinone

Ardeparin Action Pathway

Involved compounds

Ardeparin,Calcium,Phylloquinone

Argatroban Action Pathway

Involved compounds

Argatroban,Calcium,Phylloquinone

Bivalirudin Action Pathway

Involved compounds

Bivalirudin,Calcium,Phylloquinone

Lepirudin Action Pathway

Involved compounds

Calcium,Lepirudin,Phylloquinone

Ximelagatran Action Pathway

Involved compounds

Calcium,Phylloquinone,Ximelagatran

Alteplase Action Pathway

Involved compounds

Alteplase,Calcium,Phylloquinone

Anistreplase Action Pathway

Involved compounds

Anistreplase,Calcium,Phylloquinone

Streptokinase Action Pathway

Involved compounds

Calcium,Phylloquinone,Streptokinase

Tenecteplase Action Pathway

Involved compounds

Calcium,Phylloquinone,Tenecteplase

Urokinase Action Pathway

Involved compounds

Calcium,Phylloquinone,Urokinase

Reteplase Action Pathway

Involved compounds

Calcium,Phylloquinone,Reteplase

Aminocaproic Acid Action Pathway

Involved compounds

Aminocaproic acid,Calcium,Phylloquinone

Tranexamic Acid Action Pathway

Involved compounds

Calcium,Phylloquinone,Tranexamic acid

Aprotinin Action Pathway

Involved compounds

Aprotinin,Calcium,Phylloquinone

Vitamin K Metabolism

metabolic

Involved compounds

(4R,5R)-1,2-dithiane-4,5-diol,Flavin adenine dinucleotide,Methylmalonic Acid,Phylloquinone,Propanoic acid

Coagulation

physiological

Involved compounds

Calcium,Phylloquinone

Phenindione Action Pathway

Involved compounds

Calcium,Phenindione,Phylloquinone

Dicoumarol Action Pathway

Involved compounds

Calcium,Dicoumarol,Phylloquinone

Scientific references(16)

Barkhan P., Shearer M.J.

Metabolism of Vitamin K1 (Phylloquinone) in Man.

Proceedings of the Royal Society of Medicine

197770(2):93-96. doi: 10.1177/003591577707000211

PMID: 859820 DOI: 10.1177/003591577707000211

McBurney A., Shearer M.J., Barkhan P.

Preparative isolation and characterization of the urinary aglycones of vitamin K1 (phylloquinone in man.

Biochemistry Medicine

1980 Dec24(3):250-67. doi: 10.1016/0006-2944(80)90020-4

PMID: 7306367 DOI: 10.1016/0006-2944(80)90020-4

Shearer M.J., Fu X., Booth S.L.

Vitamin K nutrition, metabolism, and requirements: current concepts and future research.

Advanced Nutr

2012 Mar 13(2):182-95. doi: 10.3945/an.111.001800

PMID: 22516726 DOI: 10.3945/an.111.001800

Turck D., Bresson J.L., Burlingame B., Dean T., Fairweather-Tait S., Heinonen M., Hirsch-Ernst K.I., Mangelsdorf I., McArdle H.J., Naska A., Nowicka G., Pentieva K., Sanz Y., Siani A., Sjodin A., Stern M., Tome D., Van Loveren H., Vinceti M., Willatts P., Lamberg-Allardt C., Przyrembel H., Tetens I., Dumas C., Fabiani L., Ioannidou S., Neuhauser-Berthold M.

Dietary reference values for vitamin K.

EFSA Journal

2017 May 2215(5):e04780. doi: 10.2903/j.efsa.2017.4780. eCollection 2017 May

PMID: 32625486 DOI: 10.2903/j.efsa.2017.4780

Edson K.Z., Prasad B., Unadkat J.D., Suhara Y., Okano T., Guengerich F.P., Rettie A.E.

Cytochrome P450-dependent catabolism of vitamin K: omega-hydroxylation catalyzed by human CYP4F2 and CYP4F11.

Biochemistry

2013 Nov 1952(46):8276-85. doi: 10.1021/bi401208m. Epub 2013 Nov 7

PMID: 24138531 DOI: 10.1021/bi401208m

Imbrescia K., Moszczynski Z.

A CASE OF LIVER ANGIOSARCOMA CAUSED BY 22 YEARS OF OCCUPATIONAL EXPOSURE TO VINYL CHLORIDE MONOMER.

Epidemiology

19967(Supplement):S77. doi: 10.1097/00001648-199607001-00235

PMID: 31869059 DOI: 10.1097/00001648-199607001-00235

Jones K.S., Bluck L.J., Wang L.Y., Coward W.A.

A stable isotope method for the simultaneous measurement of vitamin K1 (phylloquinone) kinetics and absorption.

European Journal Clinical Nutr

2008 Nov62(11):1273-81. doi: 10.1038/sj.ejcn.1602859. Epub 2007 Aug 1

PMID: 17671443 DOI: 10.1038/sj.ejcn.1602859

Shearer M.J., Newman P.

Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis.

Journal Lipid Research

2014 Mar55(3):345-62. doi: 10.1194/jlr.R045559. Epub 2014 Jan 31

PMID: 24489112 DOI: 10.1194/jlr.R045559

Ingold C.J., Sergent S.R.

Vitamin K1–Phytonadione. Pediatric Injectable Drugs. 2018;:882-885. doi: 10.

37573/9781585285402

244

PMID: 32491554 DOI: 10.37573/9781585285402.244

Chin K.Y.

The Relationship between Vitamin K and Osteoarthritis: A Review of Current Evidence.

Nutrients

2020 Apr 2512(5). pii: nu12051208. doi: 10.3390/nu12051208

PMID: 32344816 DOI: 10.3390/nu12051208

Weber P.

Vitamin K and bone health.

Nutrition

2001 Oct17(10):880-7. doi: 10.1016/s0899-9007(01)00709-2

PMID: 11684396 DOI: 10.1016/s0899-9007(01)00709-2

Shioi A., Morioka T., Shoji T., Emoto M.

The Inhibitory Roles of Vitamin K in Progression of Vascular Calcification.

Nutrients

2020 Feb 2312(2). pii: nu12020583. doi: 10.3390/nu12020583

PMID: 32102248 DOI: 10.3390/nu12020583

Shearer M.J., Mallinson C.N., Webster G.R., Barkhan P.

Clearance from plasma and excretion in urine, faeces and bile of an intravenous dose of tritiated vitamin K 1 in man.

British Journal Haematol

1972 May22(5):579-88. doi: 10.1111/j.1365-2141.1972.tb05704.x

PMID: 5032096 DOI: 10.1111/j.1365-2141.1972.tb05704.x

Soedirman J.R., De Bruijn E.A., Maes R.A., Hanck A., Gruter J.

Pharmacokinetics and tolerance of intravenous and intramuscular phylloquinone (vitamin K1) mixed micelles formulation.

British Journal of Clinical Pharmacology

1996 Jun41(6):517-23. doi: 10.1046/j.1365-2125.1996.03847.x

PMID: 8799516 DOI: 10.1046/j.1365-2125.1996.03847.x

Øie S., Trenk D., Guentert T.W., Mosberg H., Jähnchen E.

Disposition of vitamin K1 after intravenous and oral administration to subjects on phenprocoumon therapy.

International Journal of Pharmaceutics

198848(1-3):223-230. doi: 10.1016/0378-5173(88)90267-0

DOI: 10.1016/0378-5173(88)90267-0

Fieser L.F.

Synthesis of Vitamin K<sub>1</sub>.

Journal of the American Chemical Society

193961(12):3467-3475. doi: 10.1021/ja01267a072

DOI: 10.1021/ja01267a072

ATC classification(1 code)

ATC B02BA01

Affected organisms(1)

Humans and other mammals

International brands(2)

Experimental properties(3)

External resources(2)

RxList Drugs.com

Protein Data Bank entries(129)

Commercial products(101)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Phylloquinone

Matched from: Phytomenadione

DB01022

CAS number

84-80-0

UNII (FDA)

S5Z3U87QHF

InChI Key (molecular fingerprint)

MBWXNTAXLNYFJB-NKFFZRIASA-N

Synonym match

95% confidence

Additional database identifiers

Drugs Product Database (DPD)

4918

ChEBI

18067

PubChem Compound

5284607

PubChem Substance

46504528

KEGG Compound

C02059

KEGG Drug

D00148

ChemSpider

4447652

BindingDB

24782

PharmGKB

PA450961

PDB

PQN

Therapeutic Targets Database

DNC001500

Wikipedia

Phytomenadione

ChEMBL

CHEMBL1550

ZINC

ZINC000003831332

RxCUI

8308

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4247

GenAtlas

GGCX

GeneCards

GGCX

GenBank Gene Database

M81592

GenBank Protein Database

184028

UniProtKB

P38435

UniProt Accession

VKGC_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3535

GenAtlas

GeneCards

GenBank Gene Database

M17262

GenBank Protein Database

339641

Guide to Pharmacology

2362

UniProtKB

P00734

UniProt Accession

THRB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1043

GenAtlas

BGLAP

GeneCards

BGLAP

GenBank Gene Database

X53698

GenBank Protein Database

36093

UniProtKB

P02818

UniProt Accession

OSTCN_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2645

GeneCards

CYP4F2

Guide to Pharmacology

1344

UniProtKB

P78329

UniProt Accession

CP4F2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:30791

GeneCards

UBIAD1

UniProtKB

Q9Y5Z9

UniProt Accession

UBIA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:23663

GenAtlas

VKORC1

GeneCards

VKORC1

GenBank Gene Database

AY423044

GenBank Protein Database

40217983

Guide to Pharmacology

2645

UniProtKB

Q9BQB6

UniProt Accession

VKOR1_HUMAN

International reference pricing

6 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $2.76/ml

To $111.13/g

Vitamin K1 10 mg/ml

$2.76/ml

Vitamin K1 Pediatric 2 mg/ml

$4.79/ml

Mephyton 5 mg tablet

$5.95/tablet

Vitamin k1 liquid

$35.00/g

Phytonadione liquid

$66.00/g

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Phytomenadione 10mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
31

Chemical identifiers

Phylloquinone

Additional database identifiers

International reference pricing

DrugBank citations

Phytomenadione 10mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science31

Chemical identifiers

Phylloquinone

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
31